Clinical Challenges
Bloodstream infections (BSIs) and sepsis are life-threatening critical conditions, with mortality rising sharply for every hour of delayed effective antimicrobial therapy. For tertiary hospital intensive care and clinical microbiology settings, conventional diagnostic workflows for positive blood cultures face four core unmet needs:
Prolonged identification and susceptibility testing delays life-saving targeted therapy
Traditional workflows require 24–72 hours for subculture, isolate identification and antimicrobial susceptibility testing (AST) after blood culture flags positive. Clinicians must rely on empiric broad-spectrum antibiotic therapy during this window, which is associated with higher treatment failure rates, elevated sepsis mortality and extended hospital length of stay.
Escalating Gram-negative antimicrobial resistance with complex mechanisms
The prevalence of multidrug-resistant (MDR) Gram-negative pathogens — including carbapenem-resistant Enterobacterales (CRE), carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa — continues to rise in inpatient settings. With diverse resistance mechanisms across carbapenemases, ESBLs and AmpC enzymes, conventional AST lags far behind clinical demand, leading to inappropriate empiric treatment and poor patient outcomes.
High barriers to centralized molecular testing extend diagnostic turnaround
Most commercial molecular BSI assays rely on standardized PCR laboratories and certified technical personnel with complex pre-processing workflows. They cannot be deployed at the point of care in ICUs, infectious disease wards or on-site microbiology labs, adding sample transport and batch-processing delays to total turnaround time (TAT) for critical samples.
Fragmented testing workflows lack an integrated rapid BSI diagnostic matrix
Bloodstream infections can be caused by Gram-positive bacteria, Gram-negative bacteria and fungi. Conventional workflows require sequential, step-by-step testing, while most single molecular panels lack flexible, targeted testing options aligned with Gram stain results, leaving no cohesive rapid diagnostic solution for severe sepsis cases.
Core Clinical Benefits
The Blood Culture Pathogen and Antimicrobial Resistance Gene (G-&AMR) Nucleic Acid Detection Kit (26 targets), paired with the Multi-Disc fully automated nucleic acid analysis platform, directly addresses the above critical care pain points:
One-stop Gram-negative pathogen identification and resistance gene profiling
The kit covers 14 clinically prevalent Gram-negative BSI pathogens and 12 core antimicrobial resistance genes (26 total targets), including Enterobacterales, non-fermentative pathogens, fastidious bacteria and hypermucovirulent Klebsiella pneumoniae. A single run delivers simultaneous pathogen identification and resistance profiling, drastically improving diagnostic efficiency.
Results in around 80 minutes to capture the sepsis golden treatment window
Total testing time is around 80 minutes, with only 1 minute of hands-on sample loading — 1–2 days faster than traditional culture and AST workflows. Rapid pathogen and resistance results enable clinicians to promptly de-escalate or adjust empiric regimens to targeted therapy, reduce sepsis mortality, shorten hospital stays and lower overall healthcare costs.
Comprehensive resistance gene coverage for early MDR pathogen warning
The panel detects five major carbapenemase genes (blaKPC, blaNDM, blaOXA-48, blaVIM, blaIMP), extended-spectrum β-lactamase genes (blaCTX-M, blaTEM, blaSHV, blaGES, blaVEB, blaPER) and the AmpC enzyme gene CMY-2, covering the most clinically relevant Gram-negative resistance mechanisms. Early identification of CRE and other MDR pathogens supports precise antibiotic selection, optimizes antimicrobial stewardship and curbs the spread of drug-resistant strains.
Complementary workflow with G+&Fungi panel for a complete BSI diagnostic solution
This G-&AMR kit is clinically paired with our 25-target Blood Culture Pathogen and Antimicrobial Resistance Gene (G+&Fungi&AMR) Detection Kit. After Gram staining of positive blood culture samples, users can select the matching panel for targeted rapid testing; for critically ill septic patients, both panels can be run in parallel on the Multi-Disc platform to deliver full pathogen coverage in a single batch, providing a comprehensive, rapid etiological diagnostic framework for severe bloodstream infections.
Low-barrier POCT deployment to reduce diagnostic TAT
Powered by the fully automated closed Multi-Disc platform, the assay requires no standardized molecular laboratory or specialized technical staff, and can be deployed directly in ICUs, infectious disease departments and clinical microbiology labs. Positive blood culture samples can be tested immediately upon flagging, eliminating transport delays and compressing overall diagnostic turnaround time.
Core Product Advantages
Critical care-oriented 26-plex panel design tailored for Gram-negative BSI
The panel covers 14 high-prevalence Gram-negative bloodstream pathogens and 12 core resistance genes, including high-priority critical care pathogens such as Acinetobacter baumannii complex, Pseudomonas aeruginosa, Stenotrophomonas maltophilia and hypermucovirulent Klebsiella pneumoniae. Resistance targets are selected for direct clinical antibiotic guidance, fully aligned with the needs of tertiary hospital intensive care and sepsis management.
Fully automated closed sample-to-result workflow
Leveraging proprietary centrifugal microfluidic technology, the kit integrates two gold-standard workflows — silica membrane-based nucleic acid extraction and multiplex real-time qPCR — within a single enclosed disposable cartridge. Only 1 minute of manual pipetting is required, with no professional molecular operation expertise needed, delivering true "load-and-go" detection.

Flexible throughput with dual-panel compatibility for diverse clinical needs
Compatible with the Multi-Disc (Model: CQ-0404) Fully Automated Nucleic Acid Analyzer, the platform supports parallel testing of 4 samples per run with full results available in around 80 minutes. The system supports mixed runs of G-&AMR and G+&Fungi&AMR panels in a single batch, flexibly accommodating positive blood culture samples with different Gram stain results, and meeting both stat critical care and routine batch testing demands.
Lyophilized reagents for room-temperature storage and transport
With our self-developed PCR reagent lyophilization process, pre-embedded lyophilized reagent beads in the microfluidic chip enable room-temperature storage and transportation, eliminating cold chain reliance and greatly reducing storage and operational costs for microbiology labs and critical care departments.
Zero cross-contamination closed cartridge system
Each sample is processed in an individual sealed disposable cartridge, with amplification products never exposed to the external environment. This design fundamentally eliminates aerosol cross-contamination, reduces laboratory quality control burden, and ensures accurate, reliable results for positive blood culture samples.
CE-compliant with validated positive blood culture compatibility
The assay is fully validated for positive blood culture samples. All 26 targets are CE-marked, meeting regulatory requirements for clinical BSI diagnosis, antimicrobial stewardship and nosocomial infection control across global markets.